- Molecular NameAmifostine
- Synonymamifostine; Amifostine Ethiofos; Aminopropylaminoethyl Thiophosphate; Apaetp; Ethiofos; Gammaphos; SAPEP; WR-1065
- Weight214.226
- Drugbank_IDDB01143
- ACS_NO20537-88-6
- Show 3D model
- LogP (experiment)-1.07
- LogP (predicted, AB/LogP v2.0)-2.28
- pka10.14, 7.26
- LogD (pH=7, predicted)-5.29
- Solubility (experiment)Soluble
- LogS (predicted, ACD/Labs)(ph=7)-0.23
- LogSw (predicted, AB/LogsW2.0)697.02
- Sw (mg/ml) (predicted, ACD/Labs)114.57
- No.of HBond Donors5
- No.of HBond Acceptors5
- No.of Rotatable Bonds7
- TPSA130.69
- StatusFDA approved
- AdministrationIntravenous
- PharmacologyA cytoprotective adjuvant used in cancer chemotherapy involving DNA-binding chemotherapeutic agents.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability100.0
- Protein binding4.0
- Volume of distribution (VD)3.5 and 7 L
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt is metabolised in the liver, by alkaline phosphatase, to the active free thiol metabolite, S-2-(3-aminopropylamino)-ethanethiol, WR-1065, and the inactive WR-33278 metabolite.
- Half life8 min
- Excretion<4% of the parent drug and metabolites are excreted in urine, WR-1065 is found in bone marrow.
- Urinary ExcretionN/A
- ClerancePlasma clearance, 2.17 L/min.
- ToxicityHypotension, nausea, vomiting. LD50 (mouse)=1000
- LD50 (rat)N/A
- LD50 (mouse)N/A